In May 2018, the US Food & Drug Administration approved the use of tofacitinib for the treatment of moderate to severe ulcerative colitis (UC). The drug tofacitinib represents the first Janus kinase (JAK) inhibitor approved in inflammatory bowel disease (IBD). This article will provide a practical approach to the clinical use of tofacitinib, as well as updates on other JAK inhibitors currently in development.